Search

Biogen Inc

Закрыт

СекторЗдравоохранение

218.55 -1.22

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

216.28

Макс.

221.5

Ключевые показатели

By Trading Economics

Доход

-639M

-320M

Продажи

258M

2.7B

P/E

Средняя по отрасли

38.469

57.366

Прибыль на акцию

3.6

Рентабельность продаж

-11.678

Сотрудники

7,500

EBITDA

-475M

78M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+5.7% upside

Дивиденды

By Acuity

Следующий отчет о доходах

29 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.4B

32B

Предыдущая цена открытия

219.77

Предыдущая цена закрытия

218.55

Новостные настроения

By Acuity

23%

77%

59 / 340 Рейтинг в Healthcare

Biogen Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

26 авг. 2026 г., 20:08 UTC

News

Biogen Inc. has chosen Veeva Systems' Veeva Vault CRM to enhance its digital strategy, with shares rising during Wednesday's session amid positive sentiment.

25 авг. 2026 г., 23:26 UTC

Biogen Inc. shares are trading roughly flat in after-market hours. Crude oil prices have declined, easing some geopolitical tensions, impacting overall market sentiment.

24 авг. 2026 г., 20:13 UTC

Biogen Inc shares are trading lower in after-market hours. Broader market conditions may be influencing trading sentiment amid U.S.-Iran tensions and inflation concerns.

21 авг. 2026 г., 20:06 UTC

Biogen Inc is trading higher since Thursday's close, reflecting positive market trends. The stock remains above its 20-day moving average despite a recent pullback.

20 авг. 2026 г., 20:01 UTC

Correlated Moves

Shares lower today amid broader market declines and ETF drop.

19 авг. 2026 г., 23:06 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Wednesday's close. The asset remains above its 20-day moving average.

17 авг. 2026 г., 19:46 UTC

Biogen Inc. shares are lower today amid routine trading, despite an unexpected rise in the New York manufacturing index supporting broader market conditions.

14 авг. 2026 г., 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting routine fluctuations. The stock remains above its 20-day moving average and near its monthly range high.

13 авг. 2026 г., 20:06 UTC

News

Wolfe Research upgraded Biogen to Outperform, raising its price target to $300, citing a promising late-stage pipeline and recent acquisition of Apellis Pharmaceuticals.

12 авг. 2026 г., 23:01 UTC

Biogen shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

11 авг. 2026 г., 23:46 UTC

Biogen Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement amid broader market focus on economic indicators.

10 авг. 2026 г., 19:36 UTC

Social Media

Biogen Inc has completed its $1 billion acquisition of RayThera. Shares are trading lower despite the strategic development and potential pipeline enhancement.

7 авг. 2026 г., 23:16 UTC

Social Media

Biogen Inc completed the acquisition of RayThera, valued at up to $1 billion, but shares are lower in after-market trading.

6 авг. 2026 г., 23:11 UTC

News

Biogen Inc. has completed its acquisition of RayThera Inc., enhancing its immunology portfolio. Shares are trading lower in after-market hours following a recent decline.

5 авг. 2026 г., 19:26 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Despite strong results, shares are trading lower amid broader market declines.

4 авг. 2026 г., 20:02 UTC

News

Mizuho raised its price target on Biogen Inc. to $241, contributing to the stock's upward movement during Tuesday's session.

3 авг. 2026 г., 23:06 UTC

Biogen Inc. shares are trading higher in after-market hours, supported by stronger-than-expected manufacturing data and positive broader market sentiment.

31 июл. 2026 г., 21:01 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Shares are higher in after-market trading following the positive results and raised EPS guidance.

30 июл. 2026 г., 19:39 UTC

Biogen Inc shares are lower in Thursday's session, reaching a low of approximately -2.86% earlier. No specific news was identified to explain the decline.

29 июл. 2026 г., 22:02 UTC

Biogen Inc shares are higher in after-market hours, maintaining a steady upward trajectory since Wednesday's close and staying above the 20-day moving average.

28 июл. 2026 г., 22:01 UTC

Biogen Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains above its 20-day moving average.

27 июл. 2026 г., 18:56 UTC

Biogen Inc. shares are lower today amid routine trading fluctuations. Broader market declines are influenced by falling oil prices ahead of the Federal Reserve meeting.

24 июл. 2026 г., 18:26 UTC

Biogen Inc. shares are higher today, continuing an upward trend since Thursday. The stock's movement appears independent of recent oil price volatility.

22 июл. 2026 г., 22:01 UTC

Biogen Inc shares are trading higher in after-market hours, reflecting an increase since Wednesday's close amid broader market volatility and rising crude oil prices.

21 июл. 2026 г., 19:46 UTC

News

BIIB trading higher after Guggenheim raised price target to $280.

20 июл. 2026 г., 22:06 UTC

Biogen Inc. shares rose slightly in after-market hours, despite broader market pressure from a decline in the Conference Board's leading economic index.

17 июл. 2026 г., 20:02 UTC

Biogen Inc's shares are lower today, continuing a downward trend since Thursday. The broader market reflects a general decline amid notable sell-offs in technology stocks.

16 июл. 2026 г., 19:02 UTC

News

Biogen partners with Synapticure to launch a virtual ataxia care program. Shares are higher today, reflecting positive sentiment since Wednesday's close.

15 июл. 2026 г., 23:36 UTC

Biogen Inc. shares declined in after-market trading, reflecting ongoing weakness amid broader market caution related to geopolitical tensions involving the U.S. and Iran.

14 июл. 2026 г., 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

Сравнение c конкурентами

Изменение цены

Biogen Inc Прогноз

Целевая цена

By TipRanks

5.7% рост

Прогноз на 12 месяцев

Средняя 234.13 USD  5.7%

Максимум 300 USD

Минимум 157 USD

Основано на мнении 27 аналитиков Wall Street, спрогнозировавших целевые цены для Biogen Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

27 ratings

17

Покупка

9

Удержание

1

Продажа

Настроения

By Acuity

59 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat